Short Interest in Surrozen, Inc. (NASDAQ:SRZN) Drops By 46.2%

Surrozen, Inc. (NASDAQ:SRZNGet Free Report) was the target of a significant decline in short interest in January. As of January 31st, there was short interest totalling 5,600 shares, a decline of 46.2% from the January 15th total of 10,400 shares. Currently, 0.3% of the company’s stock are sold short. Based on an average daily trading volume, of 11,900 shares, the days-to-cover ratio is presently 0.5 days.

Surrozen Price Performance

SRZN traded up $0.40 on Monday, reaching $9.15. 22,704 shares of the company traded hands, compared to its average volume of 13,704. The stock’s 50 day moving average price is $8.70 and its 200-day moving average price is $8.05. Surrozen has a 52-week low of $4.50 and a 52-week high of $20.70. The company has a market cap of $18.67 million, a price-to-earnings ratio of -0.53 and a beta of 0.39.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SRZN. Trustees of Columbia University in the City of New York purchased a new position in Surrozen during the fourth quarter valued at approximately $419,000. Morgan Stanley grew its stake in Surrozen by 10,427.8% in the fourth quarter. Morgan Stanley now owns 528,179 shares of the company’s stock valued at $307,000 after purchasing an additional 523,162 shares in the last quarter. Euclidean Capital LLC grew its stake in Surrozen by 63.8% in the third quarter. Euclidean Capital LLC now owns 1,315,463 shares of the company’s stock valued at $645,000 after purchasing an additional 512,500 shares in the last quarter. FMR LLC purchased a new position in Surrozen in the second quarter valued at about $744,000. Finally, Millennium Management LLC bought a new stake in Surrozen in the fourth quarter worth approximately $72,000. 51.27% of the stock is owned by hedge funds and other institutional investors.

About Surrozen

(Get Free Report)

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. The company is developing antibody-based therapeutics with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.

See Also

Receive News & Ratings for Surrozen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surrozen and related companies with's FREE daily email newsletter.